Scholar Rock stocks skyrocket after SMA drug scores at Phase III
Scholar Rock’s stock price increased by 362% after the company announced its Phase III data.
Scholar Rock’s stock price increased by 362% after the company announced its Phase III data.
As part of the development, NIAID is expected to cover the entire cost of the Phase I clinical trial.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Exscientia outline robot and AI use in drug discovery workflow
Perimeter completes enrolment for AI-assisted breast imaging trial
Microbot shifts pivotal trial up a gear with completion expected ahead of schedule
Moderna blamed after children offered £1,500 to take part in Covid-19 trial